



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1931PLC003201, www.natcopharma.co.in

12th February, 2020

Corporate Relationship Department
The BSE Ltd.
Dalal Street, Fort
Mumbai 400 001.

Scrip Code: 524816

Dear Sir,

Sub:- Outcome of Board Meeting

Further to our intimation letter dated 3rd February, 2020, we would like to inform you that the Board of Directors of the Company at their meeting held today have approved the following along with other items of business:

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2019 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time ("Listing Regulations") along with Limited Review Report of the Statutory Auditors. Please find enclosed copies of the same for your information.
2. Declared third interim dividend of Rs.3.50/- (Rupees three and fifty paise only) each per Equity share of Rs.2/- (Rupees two only) each for the financial year 2019-20 (which is 175% on the nominal value of the equity share). The date for taking on record of its shareholders eligible for the purpose of payment of third interim dividend i.e., record date is fixed as **Tuesday, the 25th February, 2020**. The payment of said interim dividend will be paid from Friday, the 28th February, 2020.
3. M/s. Grant Thornton India LLP has been appointed as Internal Auditors of the Company with effect from 1st April, 2020 till 31st March, 2021.
4. (a) Reappointed the following working Directors of the Company for a period of two years from 1st April, 2020 to 31st March, 2022 subject to the approval of the members of the Company at the Annual General Meeting to be held in the calendar year 2020 and brief profiles of them are enclosed as **Annexure - I** herewith.
 - (i) Sri V.C. Nannapaneni, DIN: 00183315, Chairman & Managing Director
 - (ii) Sri Rajeev Nannapaneni, DIN: 00183872, Vice Chairman & CEO
 - (iii) Sri P.S.R.K. Prasad, DIN: 071011140, Director & Executive Vice President(CES) and
 - (iv) Dr. D. Linga Rao, DIN: 07088404, Director & President (Technical Affairs)

M. Anuragane



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

(b) Reappointed Dr. M.U.R. Naidu, DIN: 05111014, as an Independent Director for a further term of 5 years from the conclusion of the Annual General Meeting to be held in the calendar year 2020 up to the conclusion of 42nd Annual General Meeting to be held in the calendar year 2025, subject to the approval of the members of the Company at the Annual General Meeting to be held in the calendar year 2020 and his brief profile is enclosed as **Annexure -II** herewith.

We hereby confirm that all the above mentioned reappointed Directors are not debarred from holding the office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such authority.

Please find attached herewith the Press Release.

We are also updating the financial results on the website of the Company.

This is for your information and records.

Meeting commenced at 11.00 a.m. and concluded at 3.45 p.m.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

A handwritten signature in blue ink, appearing to read "M. Adinarayana".

M. Adinarayana
Company Secretary &
V.P. (Legal & Corp. Affairs)

Encl: as above